+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver Disease Diagnostics Market By End User, By Diagnosis Technique, By Region, Industry Analysis and Forecast, 2020 - 2026

  • PDF Icon

    Report

  • 173 Pages
  • June 2020
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5129404
Description Jump to:
The Global Liver Disease Diagnostics Market size is expected to reach $40.7 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period. The liver is a vital organ that primarily functions to metabolize and detoxify toxic substances that may be harmful to the body. Liver disease refers to any illness that induces inflammation of the liver and may interfere with the proper functioning of the liver. The causes of liver disease include infection, autoimmune disorders, excessive-intake of drugs, injury, alcohol consumption, among others.

Liver diseases impact millions of people all over the world. In most developing nations, the prevalence of viral hepatitis is increasing as a result of modern advances in disease prevention, diagnosis, and treatment. Extended programs for systematic vaccination against the hepatitis B virus have also significantly reduced the number of new cases in many countries.

On the contrary, with better living conditions, the prevalence of the chronic liver disease, including non-alcoholic fatty liver disease and alcohol-related liver disease, is expected to escalate, potentially leading to more cases of end-stage liver disease (liver failure, cirrhosis, and liver cancer). During the last 30 years, visionary governments of major nations have given clear incentives for basic/clinical research, vaccination services, and drug discovery and production in the field of hepatology.

Changing habits, such as increased alcohol intake, unhealthy diets, have increased the occurrence of liver disease. Furthermore, the increasing geriatric population has contributed to significant growth in the global demand for the treatment of liver disease. There is a significant market opportunity for this market because the prevalence of disorders has become common. Government and non-government awareness programs will contribute to the growth of the liver disease treatment industry.

Nonetheless, stringent government regulations (FDA, MHRA), high prices of drug research and development, pose a crucial challenge to the liver disease treatment industry. Side effects associated with medications are a growing concern that consumer demand is expected to decline. Patent expiry and increasing general awareness of health will promote the development of the sector. New research and technology is expected to create an immense opportunity for market players.

Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited.

Strategies deployed in Liver Disease Diagnostics Market

Mar-2020: Roche announced that it received the US Food and Drug Administration (FDA) breakthrough device designation for its Elecsys GALAD score, a serum biomarker-based model. This model can predict hepatocellular carcinoma in chronic liver disease patients.

Jan-2020: Siemens launched the enhanced liver fibrosis (ELF) testing service in United States. The ELF test provides a simple, unitless numeric score via an algorithm by combining the quantitative measurements in a serum sample of three direct markers of liver fibrosis: aminoterminal propeptide of type III procollagen (PIIINP), hyaluronic acid (HA), and tissue inhibitor of metalloproteinase 1 (TIMP-1).

Nov-2019: Siemens collaborated with Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins. The collaboration was focused on nonalcoholic steatohepatitis (NASH) and liver fibrosis. This collaboration enabled Siemens Healthineers to use Galectin’s Phase 2 NASH-CX clinical trial to support regulatory filings of the ADVIA Centaur® Enhanced Liver Fibrosis (ELF) test.

Aug-2019: Boston Scientific completed the acquisition of BTG PLC, a company that develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well as specialty pharmaceuticals. The acquisition enabled it to offer best-in-class technologies, unparalleled clinical evidence and a strengthened commercial infrastructure to support physicians treating some of the most challenging diseases impacting patient health around the world.

Feb-2019: Abbott got CE Mark for the world's most sensitive rapid diagnostic test for the detection of hepatitis B surface antigen, the Determine HBsAg 2 test. This highly sensitive, easy-to-use, rapid lateral flow test enabled identification of those with the virus and facilitates linkage to care in every healthcare setting. Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV).

Dec-2017: Siemens Healthineers signed an agreement to acquire Fast Track Diagnostics (FTD), a global supplier of diagnostics tests. The acquisition is expected to strengthen and expand its presence in the field of molecular testing and precision medicine.

Oct-2017: Abbott acquired Alere, a company that provides diagnostics and point of care solutions. The acquisition helped Abbott in becoming the global leader in point of care testing, the fastest-growing segment in vitro diagnostics market. It also strengthened the company's diagnostics presence.

Aug-2017: Abbott signed an agreement with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. The agreement was focused on supplying all analytical equipment and consumables. The agreement included Abbott’s Alinity ci and Alinity h series of diagnostic instruments, as well as the company’s professional services and informatics solutions known as AlinIQ.

Scope of the Study

Market Segmentation:

By End User
  • Hospitals, Laboratories and Other End Users

By Diagnosis Technique
  • Imaging
  • Biopsy
  • Endoscopy
  • Laboratory tests and
  • Other Diagnosis Techniques

By Geography

North America
  • US
  • Canada
  • Mexico
  • Rest of North America

Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Boston Scientific Corporation
  • Siemens AG (Siemens Healthineers)
  • Bayer AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Novartis AG
  • Pfizer, Inc.
  • Randox laboratories limited

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Liver Disease Diagnostics Market, by End User
1.4.2 Global Liver Disease Diagnostics Market, by Diagnosis Technique
1.4.3 Global Liver Disease Diagnostics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Liver Disease Diagnostics Market by End User
3.1 Global Hospitals Market by Region
3.2 Global Laboratories Market by Region
3.3 Global Other End Users Market by Region
Chapter 4. Global Liver Disease Diagnostics Market by Diagnosis Technique
4.1 Global Imaging Market by Region
4.2 Global Biopsy Market by Region
4.3 Global Endoscopy Market by Region
4.4 Global Laboratory tests Market by Region
4.5 Global Other Diagnosis Techniques Market by Region
Chapter 5. Global Liver Disease Diagnostics Market by Region
5.1 North America Liver Disease Diagnostics Market
5.1.1 North America Liver Disease Diagnostics Market by End User
5.1.1.1 North America Hospitals Market by Country
5.1.1.2 North America Laboratories Market by Country
5.1.1.3 North America Other End Users Market by Country
5.1.2 North America Liver Disease Diagnostics Market by Diagnosis Technique
5.1.2.1 North America Imaging Market by Country
5.1.2.2 North America Biopsy Market by Country
5.1.2.3 North America Endoscopy Market by Country
5.1.2.4 North America Laboratory tests Market by Country
5.1.2.5 North America Other Diagnosis Techniques Market by Country
5.1.3 North America Liver Disease Diagnostics Market by Country
5.1.3.1 US Liver Disease Diagnostics Market
5.1.3.1.1 US Liver Disease Diagnostics Market by End User
5.1.3.1.2 US Liver Disease Diagnostics Market by Diagnosis Technique
5.1.3.2 Canada Liver Disease Diagnostics Market
5.1.3.2.1 Canada Liver Disease Diagnostics Market by End User
5.1.3.2.2 Canada Liver Disease Diagnostics Market by Diagnosis Technique
5.1.3.3 Mexico Liver Disease Diagnostics Market
5.1.3.3.1 Mexico Liver Disease Diagnostics Market by End User
5.1.3.3.2 Mexico Liver Disease Diagnostics Market by Diagnosis Technique
5.1.3.4 Rest of North America Liver Disease Diagnostics Market
5.1.3.4.1 Rest of North America Liver Disease Diagnostics Market by End User
5.1.3.4.2 Rest of North America Liver Disease Diagnostics Market by Diagnosis Technique
5.2 Europe Liver Disease Diagnostics Market
5.2.1 Europe Liver Disease Diagnostics Market by End User
5.2.1.1 Europe Hospitals Market by Country
5.2.1.2 Europe Laboratories Market by Country
5.2.1.3 Europe Other End Users Market by Country
5.2.2 Europe Liver Disease Diagnostics Market by Diagnosis Technique
5.2.2.1 Europe Imaging Market by Country
5.2.2.2 Europe Biopsy Market by Country
5.2.2.3 Europe Endoscopy Market by Country
5.2.2.4 Europe Laboratory tests Market by Country
5.2.2.5 Europe Other Diagnosis Techniques Market by Country
5.2.3 Europe Liver Disease Diagnostics Market by Country
5.2.3.1 Germany Liver Disease Diagnostics Market
5.2.3.1.1 Germany Liver Disease Diagnostics Market by End User
5.2.3.1.2 Germany Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.2 UK Liver Disease Diagnostics Market
5.2.3.2.1 UK Liver Disease Diagnostics Market by End User
5.2.3.2.2 UK Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.3 France Liver Disease Diagnostics Market
5.2.3.3.1 France Liver Disease Diagnostics Market by End User
5.2.3.3.2 France Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.4 Russia Liver Disease Diagnostics Market
5.2.3.4.1 Russia Liver Disease Diagnostics Market by End User
5.2.3.4.2 Russia Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.5 Spain Liver Disease Diagnostics Market
5.2.3.5.1 Spain Liver Disease Diagnostics Market by End User
5.2.3.5.2 Spain Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.6 Italy Liver Disease Diagnostics Market
5.2.3.6.1 Italy Liver Disease Diagnostics Market by End User
5.2.3.6.2 Italy Liver Disease Diagnostics Market by Diagnosis Technique
5.2.3.7 Rest of Europe Liver Disease Diagnostics Market
5.2.3.7.1 Rest of Europe Liver Disease Diagnostics Market by End User
5.2.3.7.2 Rest of Europe Liver Disease Diagnostics Market by Diagnosis Technique
5.3 Asia Pacific Liver Disease Diagnostics Market
5.3.1 Asia Pacific Liver Disease Diagnostics Market by End User
5.3.1.1 Asia Pacific Hospitals Market by Country
5.3.1.2 Asia Pacific Laboratories Market by Country
5.3.1.3 Asia Pacific Other End Users Market by Country
5.3.2 Asia Pacific Liver Disease Diagnostics Market by Diagnosis Technique
5.3.2.1 Asia Pacific Imaging Market by Country
5.3.2.2 Asia Pacific Biopsy Market by Country
5.3.2.3 Asia Pacific Endoscopy Market by Country
5.3.2.4 Asia Pacific Laboratory tests Market by Country
5.3.2.5 Asia Pacific Other Diagnosis Techniques Market by Country
5.3.3 Asia Pacific Liver Disease Diagnostics Market by Country
5.3.3.1 China Liver Disease Diagnostics Market
5.3.3.1.1 China Liver Disease Diagnostics Market by End User
5.3.3.1.2 China Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.2 Japan Liver Disease Diagnostics Market
5.3.3.2.1 Japan Liver Disease Diagnostics Market by End User
5.3.3.2.2 Japan Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.3 India Liver Disease Diagnostics Market
5.3.3.3.1 India Liver Disease Diagnostics Market by End User
5.3.3.3.2 India Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.4 South Korea Liver Disease Diagnostics Market
5.3.3.4.1 South Korea Liver Disease Diagnostics Market by End User
5.3.3.4.2 South Korea Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.5 Singapore Liver Disease Diagnostics Market
5.3.3.5.1 Singapore Liver Disease Diagnostics Market by End User
5.3.3.5.2 Singapore Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.6 Malaysia Liver Disease Diagnostics Market
5.3.3.6.1 Malaysia Liver Disease Diagnostics Market by End User
5.3.3.6.2 Malaysia Liver Disease Diagnostics Market by Diagnosis Technique
5.3.3.7 Rest of Asia Pacific Liver Disease Diagnostics Market
5.3.3.7.1 Rest of Asia Pacific Liver Disease Diagnostics Market by End User
5.3.3.7.2 Rest of Asia Pacific Liver Disease Diagnostics Market by Diagnosis Technique
5.4 LAMEA Liver Disease Diagnostics Market
5.4.1 LAMEA Liver Disease Diagnostics Market by End User
5.4.1.1 LAMEA Hospitals Market by Country
5.4.1.2 LAMEA Laboratories Market by Country
5.4.1.3 LAMEA Other End Users Market by Country
5.4.2 LAMEA Liver Disease Diagnostics Market by Diagnosis Technique
5.4.2.1 LAMEA Imaging Market by Country
5.4.2.2 LAMEA Biopsy Market by Country
5.4.2.3 LAMEA Endoscopy Market by Country
5.4.2.4 LAMEA Laboratory tests Market by Country
5.4.2.5 LAMEA Other Diagnosis Techniques Market by Country
5.4.3 LAMEA Liver Disease Diagnostics Market by Country
5.4.3.1 Brazil Liver Disease Diagnostics Market
5.4.3.1.1 Brazil Liver Disease Diagnostics Market by End User
5.4.3.1.2 Brazil Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.2 Argentina Liver Disease Diagnostics Market
5.4.3.2.1 Argentina Liver Disease Diagnostics Market by End User
5.4.3.2.2 Argentina Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.3 UAE Liver Disease Diagnostics Market
5.4.3.3.1 UAE Liver Disease Diagnostics Market by End User
5.4.3.3.2 UAE Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.4 Saudi Arabia Liver Disease Diagnostics Market
5.4.3.4.1 Saudi Arabia Liver Disease Diagnostics Market by End User
5.4.3.4.2 Saudi Arabia Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.5 South Africa Liver Disease Diagnostics Market
5.4.3.5.1 South Africa Liver Disease Diagnostics Market by End User
5.4.3.5.2 South Africa Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.6 Nigeria Liver Disease Diagnostics Market
5.4.3.6.1 Nigeria Liver Disease Diagnostics Market by End User
5.4.3.6.2 Nigeria Liver Disease Diagnostics Market by Diagnosis Technique
5.4.3.7 Rest of LAMEA Liver Disease Diagnostics Market
5.4.3.7.1 Rest of LAMEA Liver Disease Diagnostics Market by End User
5.4.3.7.2 Rest of LAMEA Liver Disease Diagnostics Market by Diagnosis Technique
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.1.5.3 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Approvals:
6.3 Boston Scientific Corporation
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Acquisition and Mergers:
6.4 Siemens AG (Siemens Healthineers)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Acquisition and Mergers:
6.4.5.3 Product Launches and Product Expansions:
6.5 Bayer AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Merck & Co., Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10 Randox Laboratories Limited
6.10.1 Company Overview

Companies Mentioned

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Boston Scientific Corporation
  • Siemens AG (Siemens Healthineers)
  • Bayer AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Novartis AG
  • Pfizer, Inc.
  • Randox laboratories limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Liver Disease Diagnostics Market by Diagnosis Technique, End-user - Global Forecast 2025-2030 - Product Image

Liver Disease Diagnostics Market by Diagnosis Technique, End-user - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Liver Disease Diagnostics Market Size, Share and Trends Analysis Report by Diagnosis Technique (Imaging, Laboratory Tests, Endoscopy, Biopsy), Disease (NAFLD, NASH, Fibrosis, Cirrhosis), End-use (Hospitals, Laboratories), and Region 2024-2030 - Product Image

Liver Disease Diagnostics Market Size, Share and Trends Analysis Report by Diagnosis Technique (Imaging, Laboratory Tests, Endoscopy, Biopsy), Disease (NAFLD, NASH, Fibrosis, Cirrhosis), End-use (Hospitals, Laboratories), and Region 2024-2030

  • Report
  • 80 Pages
  • Global
From
Liver Disease Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Liver Disease Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Liver Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Liver Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Liver Cancer Diagnostics - Global Strategic Business Report - Product Image

Liver Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 88 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.